Latest Trials
Latest News
FAQ
Pharmaceutical Companies
Pharma Details
Michael Ayers
🇺🇸
United States
Country
🇺🇸
United States
Ownership
-
Employees
-
Market Cap
-
Website
Clinical Trials
Related News
Effect of Mavacamten Treatment on Coronary Flow Reserve in oHCM
Recruiting
Conditions
Obstructive Hypertrophic Cardiomyopathy
Interventions
Drug: mavacamten
Subscribe
First Posted Date
2023-09-05
Last Posted Date
2024-11-06
Lead Sponsor
Michael Ayers
Target Recruit Count
20
Registration Number
NCT06023186
Locations
🇺🇸
University of Virginia, Charlottesville, Virginia, United States
Subscribe
Prev
1
Next
© Copyright 2024. All Rights Reserved by MedPath
Home
Terms & Conditions
Privacy Policy